Clinical Scorecard: Case Study: Rapid Development of Pulmonary Embolism After Initiating Antipsychotic Combination Therapy in an Acute Psychiatric Environment

At a Glance

Key Highlights

• Rapid onset of PE within hours of initiating antipsychotic treatment.
• Increased VTE risk associated with antipsychotic medications, especially in newly initiated users.
• Classic and psychiatric-specific risk factors for VTE include immobility, metabolic syndrome, and lack of physical activity.
• Anticoagulation successfully treated the PE in the presented case.
• Heightened clinical vigilance is necessary for early-phase antipsychotic therapy.

Guideline-Based Recommendations

Diagnosis

• Consider PE in patients with acute deterioration after initiating antipsychotic therapy.

Management

• Initiate anticoagulation therapy upon confirmation of PE.

Monitoring & Follow-up

• Assess VTE and bleeding risk in all acute psychiatric inpatients.
• Educate patients about the risks of VTE associated with antipsychotic therapy.

Risks

• Routine pharmacological prophylaxis is not recommended in low-risk patients; consider in high-risk scenarios.

Patient & Prescribing Data

Combination therapy with olanzapine, quetiapine, levomepromazine, and lorazepam may increase VTE risk; monitor patients closely for signs of VTE.

Clinical Best Practices

• Conduct thorough risk assessments for VTE in psychiatric patients.
• Monitor for signs of PE, especially in the early treatment phase of antipsychotics.
• Educate healthcare providers about the potential rapid onset of VTE in patients receiving antipsychotics.
• Encourage interdisciplinary collaboration in monitoring VTE risk in psychiatric settings.

References

• NICE guideline NG89
• Meta-analysis on antipsychotics and VTE risk
• Study on DVT incidence in catatonic inpatients